Degarelix (Firmagon)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.[1][2][3]
Route: SC
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 12/24/2008: FDA approved "for treatment of patients with advanced prostate cancer."

Also known as

  • Code name: FE200486
  • Generic name: degarelix acetate
  • Brand name: Firmagon


  1. 1.0 1.1 1.2 Degarelix (Firmagon) package insert
  2. Degarelix (Firmagon) package insert (locally hosted backup)
  3. Firmagon manufacturer's website
  4. Degarelix (Firmagon) patient drug information (UpToDate)